The Absolute Effect / Oncology Evidence / Complete evidence index
Pancreatic Cancer Evidence
Evidence across neoadjuvant, adjuvant and advanced pancreatic ductal adenocarcinoma.
CONKO-001
Discipline: Medical · Setting: Adjuvant / Postoperative
Adjuvant gemcitabine after pancreatic resection.
ESPAC-4
Discipline: Medical · Setting: Adjuvant / Postoperative
Gemcitabine-capecitabine versus gemcitabine after resection.
NAPOLI-1
Discipline: Medical · Setting: Relapsed / Refractory
Liposomal irinotecan plus 5-FU/leucovorin after gemcitabine.
PREOPANC-1
Discipline: Radiation · Setting: Neoadjuvant / Preoperative
Neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery.
PREOPANC-2
Discipline: Medical · Setting: Neoadjuvant / Preoperative
Neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy.
PRODIGE 24/PA6
Discipline: Medical · Setting: Adjuvant / Postoperative
Modified FOLFIRINOX versus gemcitabine after resection.
PRODIGE 4/ACCORD 11
Discipline: Medical · Setting: Advanced / Metastatic
FOLFIRINOX versus gemcitabine in metastatic PDAC.
NAPOLI-3
Discipline: Medical · Setting: Advanced / Metastatic
NALIRIFOX versus gemcitabine/nab-paclitaxel in metastatic PDAC.